Tab navigation


In 2018 there were an estimated 18 million incidents of cancer globally. In China, the age standardisation rate for cancer was a little over 200 per 100,000 in 2018 – a figure likely to grow significantly as the population ages.

Consumers are increasingly looking for solutions to cope with the risk of cancer and sales of critical illness products have increased sharply in China.

This is a great opportunity for insurers; but not one without risk. Definitions of cancer have not been standardised and the industry must work with regulators to negate the danger of over diagnosis. Insurers must also be wary of anti-selection as new technologies, such as liquid biopsies, increasingly facilitate early cancer detection, without appearing on medical records.

Join Swiss Re Institute in Beijing to discuss with medical experts, health service administrators, regulators and the insurance community to discuss the complex landscape of cancer in China. We believe there are solutions that can benefit all parties; but they will not happen without dialogue and mutual understanding.